Compare OLED & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLED | CPRX |
|---|---|---|
| Founded | 1985 | 2002 |
| Country | United States | United States |
| Employees | 469 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | 1996 | 2006 |
| Metric | OLED | CPRX |
|---|---|---|
| Price | $78.06 | $31.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $125.00 | $35.00 |
| AVG Volume (30 Days) | 713.3K | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | 9.25 | ★ 28.24 |
| EPS | ★ 0.76 | 0.50 |
| Revenue | ★ $650,611,000.00 | $119,072,803.00 |
| Revenue This Year | $5.88 | $9.20 |
| Revenue Next Year | $10.36 | $10.51 |
| P/E Ratio | $103.61 | ★ $62.94 |
| Revenue Growth | 0.45 | ★ 16.39 |
| 52 Week Low | $77.15 | $19.05 |
| 52 Week High | $161.92 | $32.56 |
| Indicator | OLED | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.00 | 70.75 |
| Support Level | N/A | $31.25 |
| Resistance Level | $96.40 | $32.56 |
| Average True Range (ATR) | 4.02 | 0.04 |
| MACD | -0.70 | -0.08 |
| Stochastic Oscillator | 9.14 | 75.00 |
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. The large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.